HALO:NASDAQ
Halozyme Therapeutics, Inc.
91,35 USD
arrow_downward
−1,82%(−1,69) 1 D
91,35 USD
0,00% (0,00)
bedtimeEtter stengetid
Stengt: 20. nov., 16:00:01 GMT-5 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for HALO …
Åpne
93,64 USD
Høy
93,64 USD
Lav
90,79 USD
Markedsverdi
10,41 mrd.
Snittvolum
2,35 mill.
Volum
1,50 mill.
P/E-forhold
23,25
52 u høy
133,96 USD
52 u lav
61,22 USD
EPS
3,93 USD
Beta
0,92
Utestående aksjer
114,01 mill.
Antall ansatte
423
Åpne
93,64 USD
Høy
93,64 USD
Lav
90,79 USD
Markedsverdi
10,41 mrd.
Snittvolum
2,35 mill.
Volum
1,50 mill.
P/E-forhold
23,25
52 u høy
133,96 USD
52 u lav
61,22 USD
EPS
3,93 USD
Beta
0,92
Utestående aksjer
114,01 mill.
Antall ansatte
423
Nyhetssaker
Fra nettkilder og nyhetspartnere
Zacks
·
for 8 timer siden
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Investing.com Canada
·
for 10 timer siden
H.C. Wainwright reiterates Halozyme stock rating after Germany ruling By Investing.com
Benzinga
·
for 1 døgn siden
Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure
Yahoo Finance
·
for 1 døgn siden
HALO Stock Hits Over 3-Month Lows, As German Court Overturns Temporary Ban On Merck’s Keytruda SC
Profil
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
Om Halozyme Therapeutics, Inc.
Administrerende direktørHelen I. Torley
Ansatte423
Grunnlagt1998
HovedkontorSan Diego, California, USA
SektorHealth Care
Bransje-
Nettstedhalozyme.com